The long-acting GLP-1 analogue, semaglutide, which is currently approved for the treatment of T2D and obesity [11,12], has been demonstrated to improve cardiorenal outcomes in patients with T2D [9,10]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.